The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation (CSWF) and sponsored by CStone Pharmaceuticals (HKG: 2616), has officially been launched. This initiative aims to raise awareness and support for AML, a disease that disproportionately affects the elderly and progresses rapidly.
AML Context
Acute myeloid leukemia (AML) is the most common type of adult leukemia, with the majority of patients being elderly. In recent years, the incidence rate of AML in China has been increasing annually. According to the latest data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, there were approximately 80,000 new leukemia patients in China, with 70% being diagnosed with AML.
CStone Pharma’s Commitment
CStone Pharmaceuticals has a history of sponsoring and conducting multiple public welfare activities since its foundation. The company has been particularly active in patient assistance programs, including one for its RET inhibitor Gavreto (pralsetinib), a drug in-licensed from US-based biotech Blueprint Medicines in June 2018. This latest initiative underscores CStone’s ongoing commitment to improving patient outcomes and supporting public health initiatives.
Future Implications
The launch of the AML public welfare project marks a significant step in raising awareness and providing support for patients affected by this aggressive form of leukemia. By partnering with the China Social Welfare Foundation, CStone Pharmaceuticals aims to enhance public understanding of AML and contribute to the development of better treatment options and support systems for patients.-Fineline Info & Tech
